Valerie Defraine
Overview
Explore the profile of Valerie Defraine including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
295
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Defraine V, Fauvart M, Michiels J
Drug Resist Updat
. 2018 Jun;
38:12-26.
PMID: 29857815
In addition to the well-known strategies of antibiotic resistance and biofilm formation, bacterial populations possess an additional survival strategy to endure hostile environments or antibiotic exposure. A small fraction of...
2.
Defraine V, Liebens V, Loos E, Swings T, Weytjens B, Fierro C, et al.
Front Microbiol
. 2018 Feb;
9:129.
PMID: 29472905
The ever increasing multidrug-resistance of clinically important pathogens and the lack of novel antibiotics have resulted in a true antibiotic crisis where many antibiotics are no longer effective. Further complicating...
3.
Defraine V, Verstraete L, Van Bambeke F, Anantharajah A, Townsend E, Ramage G, et al.
Front Microbiol
. 2018 Jan;
8:2585.
PMID: 29312259
We recently described the novel anti-persister compound 1-[(2,4-dichlorophenethyl)amino]-3-phenoxypropan-2-ol (SPI009), capable of directly killing persister cells of the Gram-negative pathogen . This compound also shows antibacterial effects against non-persister cells, suggesting...
4.
Liebens V, Defraine V, Knapen W, Swings T, Beullens S, Corbau R, et al.
Antimicrob Agents Chemother
. 2017 Jun;
61(9).
PMID: 28630188
Antibiotics typically fail to completely eradicate a bacterial population, leaving a small fraction of transiently antibiotic-tolerant persister cells intact. Persisters are therefore seen to be a major cause of treatment...
5.
Gerits E, Defraine V, Vandamme K, De Cremer K, De Brucker K, Thevissen K, et al.
Antimicrob Agents Chemother
. 2016 Dec;
61(3).
PMID: 27993858
The spread of antibiotic resistance and the challenges associated with antiseptics such as chlorhexidine have necessitated a search for new antibacterial agents against oral bacterial pathogens. As a result of...
6.
Defraine V, Schuermans J, Grymonprez B, Govers S, Aertsen A, Fauvart M, et al.
Antimicrob Agents Chemother
. 2016 Mar;
60(6):3480-8.
PMID: 27021321
Bacteriophage-encoded endolysins have shown promise as a novel class of antibacterials with a unique mode of action, i.e., peptidoglycan degradation. However, Gram-negative pathogens are generally not susceptible due to their...
7.
Liebens V, Defraine V, Fauvart M
Methods Mol Biol
. 2015 Oct;
1333:113-20.
PMID: 26468104
Despite its clinical relevance and the fact that the phenomenon of persistence was discovered in the 1940s, little is known about the mechanisms behind persister cell formation. Research in this...
8.
Briers Y, Walmagh M, Grymonprez B, Biebl M, Pirnay J, Defraine V, et al.
Antimicrob Agents Chemother
. 2014 Apr;
58(7):3774-84.
PMID: 24752267
Artilysins constitute a novel class of efficient enzyme-based antibacterials. Specifically, they covalently combine a bacteriophage-encoded endolysin, which degrades the peptidoglycan, with a targeting peptide that transports the endolysin through the...
9.
Liebens V, Defraine V, Van der Leyden A, De Groote V, Fierro C, Beullens S, et al.
Pathog Dis
. 2014 Apr;
71(1):39-54.
PMID: 24692291
A major cause of treatment failure of infections caused by Pseudomonas aeruginosa is the presence of antibiotic-insensitive persister cells. The mechanism of persister formation in P. aeruginosa is largely unknown,...